Evogence Biologics provides a proprietary mammalian cell‑based display platform that prioritizes developability during antibody discovery, enabling rapid identification of high‑affinity, stable candidates with favorable manufacturability. The platform supports both monoclonal and bispecific programs and is offered through licensing or co‑development partnerships to pharmaceutical and biotech companies seeking efficient, high‑quality antibody engineering solutions.
Funding
Funding not disclosed
Founders
Product
Problem
Biopharma companies often face challenges in discovering antibody candidates that combine high affinity with favorable developability attributes, leading to costly late-stage failures and lengthy optimization cycles.
Solution
Evogence Biologics offers a proprietary mammalian display platform designed to prioritize developability from the earliest stages of antibody discovery. The platform enables rapid identification of functional antibodies with strong biophysical and manufacturability profiles, reducing the need for extensive downstream engineering. By integrating data‑driven decision making and advanced engineering workflows, Evogence supports both conventional and bispecific antibody programs. The company collaborates with partners through platform licensing and co‑development arrangements, delivering high‑quality candidates that can accelerate preclinical and clinical timelines.
Target Audience
Primary customers are pharmaceutical and biotechnology companies seeking robust antibody discovery and engineering solutions, including those developing therapeutic monoclonal and bispecific antibodies.
Features
- Mammalian cell‑based display system optimized for high‑throughput screening of antibody libraries
- Developability‑first selection criteria that assess stability, aggregation propensity, and manufacturability early in discovery
- Integrated antibody engineering pipelines for affinity maturation, humanization, and Fc optimization
- Dedicated bispecific antibody discovery capability leveraging the same display technology
- Flexible partnership models including platform licensing and joint co‑development projects